On October 16, 2018 Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, reported that results of the Oraxol (oral paclitaxel and HM30181A) pharmacokinetics and phase II clinical trial in the treatment of breast cancer patients who failed previous chemotherapies will be presented on October 21, 2018 at a Poster Discussion in the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress in Munich, Germany (Press release, Athenex, OCT 16, 2018, View Source;p=RssLanding&cat=news&id=2371846 [SID1234529936]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This study has completed patient recruitment and encouraging positive efficacy and safety data will be reported. Oraxol was granted the Promising Innovative Medicine Designation by the United Kingdom Medicines and Healthcare Products Regulatory Agency in December 2017.

Details on the Poster Discussion session are listed below.

Title: Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients
Presentation Number: 287PD
Presenter: Ming-Shen Dai (Taipei, TW)
Session Name: Poster Discussion session – Breast cancer, metastatic
Date / Time / Location: October 21, 2018; 9:15 AM – 10:30 AM (local time); ICM – Room 1, ICM München
The Poster presentation at ESMO (Free ESMO Whitepaper) will be available on the ESMO (Free ESMO Whitepaper) website at 12:00 CEST on Friday, October 19, 2018.